Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | CTSG | P08311 | 1/20 | 0.57 |
| ▸ | CMA1 | P23946 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16770417 | 0.85 | ALDH1A1 (0.55) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL19293154 | 0.83 | NPC1 (0.58) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL13033202 | 0.83 | CTSG (0.51) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL16656671 | 0.81 | ALDH1A1 (0.58) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL16449189 | 0.81 | PSMB5 (0.60) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL25925096 | 0.80 | GAA (0.56) | ALDH1A1FAAH | |
| SCHEMBL23489727 | 0.80 | ALDH1A1 (0.63) | CTSGCMA1ALDH1A1 | |
| SCHEMBL2806565 | 0.79 | FAAH (0.67) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL2806570 | 0.79 | FAAH (0.67) | HDAC1HDAC6HDAC3HDAC4HDAC7 | |
| SCHEMBL21915761 | 0.79 | HDAC3 (0.50) | HDAC1HDAC6HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175037-B2 | Neuromedin U derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9175037-B2 | Neuromedin U derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-03 | — | — | US | disclosed |
| US-20120094899-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094899-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2206721-A1 | NEUROMEDIN U DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286035-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | HDAC1 4807/4885HDAC6 3652/4885HDAC3 4797/4885 |
| US-20120094899-A1 | NEUROMEDIN U DERIVATIVE | NMUR1, NMUR2, NMBR | HDAC1 4760/4885HDAC6 4336/4885HDAC3 4768/4885 |
| US-20110212890-A1 | METASTIN DERIVATIVE AND USE THEREOF | GNRHR, SHBG, LHCGR | HDAC1 1536/4885HDAC6 1629/4885HDAC3 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.